| 1 |
35585779 | Lessons from 20 years with COX-2 inhibitors: importance of dose-response considerations and fair play in comparative trials. | 2022 May 18 |
1 |
| 2 |
34182020 | Recategorization of Non-Aspirin Nonsteroidal Anti-inflammatory Drugs According to Clinical Relevance: Abandoning the Traditional NSAID Terminology. | 2021 Nov |
1 |
| 3 |
32236281 | Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo. | 2020 Apr 28 |
3 |
| 4 |
32368976 | Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives. | 2020 |
1 |
| 5 |
30391698 | New benzimidazothiazole derivatives as anti-inflammatory, antitumor active agents: Synthesis, in-vitro and in-vivo screening and molecular modeling studies. | 2019 Mar |
1 |
| 6 |
30710016 | Interactions of fatty acids, nonsteroidal anti-inflammatory drugs, and coxibs with the catalytic and allosteric subunits of cyclooxygenases-1 and -2. | 2019 Feb 1 |
1 |
| 7 |
30737317 | A seven-step plan for becoming a moderately rich and famous biochemist. | 2019 Feb 8 |
1 |
| 8 |
30842737 | The H2S-Releasing Naproxen Derivative ATB-346 and the Slow-Release H2S Donor GYY4137 Reduce Intestinal Inflammation and Restore Transit in Postoperative Ileus. | 2019 |
1 |
| 9 |
30878890 | Novel aryl carboximidamide and 3-aryl-1,2,4-oxadiazole analogues of naproxen as dual selective COX-2/15-LOX inhibitors: Design, synthesis and docking studies. | 2019 Apr |
1 |
| 10 |
29182950 | Design, synthesis, anti-inflammatory antitumor activities, molecular modeling and molecular dynamics simulations of potential naprosyn® analogs as COX-1 and/or COX-2 inhibitors. | 2018 Feb |
2 |
| 11 |
29235601 | Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines. | 2018 Jan 2 |
2 |
| 12 |
30028133 | From Naproxen Repurposing to Naproxen Analogues and Their Antiviral Activity against Influenza A Virus. | 2018 Aug 23 |
1 |
| 13 |
30216848 | Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking. | 2018 Oct 5 |
1 |
| 14 |
27826802 | Clinical Pharmacology and Cardiovascular Safety of Naproxen. | 2017 Apr |
1 |
| 15 |
26634864 | Naproxen sodium decreases prostaglandins secretion from cultured human endometrial stromal cells modulating metabolizing enzymes mRNA expression. | 2016 |
3 |
| 16 |
27324742 | Rational Design and Synthesis of Biologically Active Disubstituted 2(3H) Furanones and Pyrrolone Derivatives as Potent and Safer Non Steroidal Anti-inflammatory Agents. | 2016 |
1 |
| 17 |
24327721 | Naproxen induces cell-cycle arrest and apoptosis in human urinary bladder cancer cell lines and chemically induced cancers by targeting PI3K. | 2014 Feb |
2 |
| 18 |
24697248 | Cardiovascular events associated with the long-term use of NSAIDs: a review of randomized controlled trials and observational studies. | 2014 May |
1 |
| 19 |
25006185 | Nonsteroidal anti-inflammatory drugs and cardiovascular outcomes in women: results from the women's health initiative. | 2014 Jul |
1 |
| 20 |
22178666 | Biological evaluation of cobalt(II) complexes with non-steroidal anti-inflammatory drug naproxen. | 2012 Feb |
1 |
| 21 |
22221151 | Pharmacological synergy: the next frontier on therapeutic advancement for migraine. | 2012 Apr |
1 |
| 22 |
21830840 | Randomized controlled trials of COX-2 inhibitors: an analysis of doses used and trends over time to investigate implications for comparative safety. | 2011 Sep 1 |
1 |
| 23 |
20810665 | Molecular basis for cyclooxygenase inhibition by the non-steroidal anti-inflammatory drug naproxen. | 2010 Nov 5 |
3 |
| 24 |
19345936 | Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. | 2009 |
1 |
| 25 |
19563267 | The search for new COX-2 inhibitors: a review of 2002 - 2008 patents. | 2009 Sep |
1 |
| 26 |
18397691 | Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. | 2008 Apr |
1 |
| 27 |
17594377 | In patients with temporomandibular disorders, do particular interventions influence oral health-related quality of life? A qualitative systematic review of the literature. | 2007 Jun |
1 |
| 28 |
19075973 | Targeting inhibition of COX-2: a review of patents, 2002-2006. | 2007 Jun |
1 |
| 29 |
17080978 | Review: selective COX-2 inhibitors increase vascular events more than placebo and naproxen, but not more than other NSAIDs. | 2006 Nov-Dec |
1 |
| 30 |
17213165 | Review: Selective COX 2 inhibitors increase vascular events more than placebo and naproxen but not more than other NSAIDs. | 2006 Dec |
1 |
| 31 |
16083531 | Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray? | 2005 Aug |
1 |
| 32 |
16372823 | Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. | 2005 |
1 |
| 33 |
14510637 | Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms. | 2004 Feb 1 |
1 |
| 34 |
12445672 | Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. | 2003 Jan 10 |
1 |
| 35 |
12852704 | Valdecoxib: a review. | 2003 Mar |
1 |
| 36 |
14655004 | [Clinical pharmacology of the selective COX-2 inhibitors]. | 2003 Dec |
1 |
| 37 |
12508788 | A selective COX-2 inhibitor, meloxicam, as a treatment option in patients with juvenile idiopathic arthritis and gastrointestinal side effects from naproxen. | 2002 Nov-Dec |
1 |
| 38 |
11171823 | Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. | 2001 Mar |
1 |
| 39 |
11696466 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. | 2001 Nov 6 |
1 |
| 40 |
10909271 | Isolation of (S)-(+)-naproxene from Musa acuminata. Inhibitory effect of naproxene and its 7-methoxy isomer on constitutive COX-1 and inducible COX-2. | 2000 Jun |
4 |
| 41 |
11028250 | Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. | 2000 Oct |
1 |